The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus
Abstract Background Guidelines classify sacubitril/valsartan as a significant part of medical treatment of heart failure with reduced ejection fraction (HFrEF). Data have shown that the HbA1c levels in patients with diabetes mellitus could be impacted by sacubitril/valsartan. A possible positive eff...
Main Authors: | Ibrahim El‐Battrawy, Jonathan Demmer, Mohammad Abumayyaleh, Carina Crack, Christina Pilsinger, Xiaobo Zhou, Andreas Mügge, Ibrahim Akin, Assem Aweimer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.14239 |
Similar Items
-
Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy
by: Mohammad Abumayyaleh, et al.
Published: (2021-10-01) -
Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials
by: Xue-Hui Liu, et al.
Published: (2022-09-01) -
Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Ruxin Wang, et al.
Published: (2022-07-01) -
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01) -
What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)